What Parkinson's Disease Does to the Brain

In Shoreditch, London, in the spring of 1817, a surgeon-apothecary named James Parkinson sat at his desk at 1 Hoxton Square and drafted a manuscript that would run to sixty-six pages. He titled it An Essay on the Shaking Palsy. It rested on only six cases, three of them his own patients and three of them men he had simply watched on the streets of his neighborhood, observing the way they shook at rest, leaned forward as they walked, and seemed to hurry against their own will. From those few observations he assembled the first coherent clinical portrait of a disease that had surely afflicted people for millennia but had never been named.

Half a century later, the great French neurologist Jean-Martin Charcot, working at the Salpêtrière hospital in Paris, read Parkinson's essay, refined the description, and gave the disorder the name we still use. What neither man could have known is that everything they were watching, the tremor, the slowness, the stoop, traced back to the slow death of a cluster of cells in the midbrain so small you could cover it with a fingertip. This article follows the trail from that 1817 desk to the molecular machinery we now understand, and explains both what we can treat and what we still cannot.

A Surgeon's Six Patients and the Birth of a Diagnosis

Parkinson called the condition paralysis agitans, the shaking palsy, and the Latin name captured a genuine paradox. His patients were not paralyzed in the ordinary sense, since their muscles still worked, yet they were robbed of the fluent, automatic control that healthy movement depends on. He identified three features that remain central to the diagnosis today. There was a tremor that appeared when the hand was at rest and quieted when the patient reached for something. There was a peculiar gait, festinant, meaning hurrying, in which the body seemed to chase its own forward-tilted center of gravity in short accelerating steps. And there was the stooped posture, the trunk bent forward as if perpetually bracing into a wind.

When Charcot took up the disorder in the 1870s at the Salpêtrière, he added a fourth element that Parkinson had underweighted, the rigidity of the limbs, a stiffness a physician can feel directly when bending a patient's arm. Charcot also insisted, generously, that the disease be named for the obscure London surgeon who first described it rather than for himself. The label Parkinson's disease dates from this period.

The Clinical Tetrad and the Years That Come Before It

Modern diagnostic criteria organize the motor picture around four signs, and it helps to understand which one carries the most weight. The cardinal feature is bradykinesia, a slowness in initiating and executing movement, and no diagnosis of Parkinson's disease is made without it. Alongside bradykinesia a clinician looks for at least one of three partners. The first is the resting tremor, classically a four-to-six-hertz oscillation described as pill-rolling because the thumb and forefinger move as though rolling a small pill, and it characteristically vanishes during voluntary action. The second is rigidity, often felt as a smooth lead-pipe resistance, sometimes broken into a ratcheting cogwheel quality when a tremor is superimposed on the stiffness. The third is postural instability, the loss of the reflexes that keep us upright, which tends to arrive late and brings the danger of falls.

What is striking, and clinically important, is that the disease usually announces itself quietly long before any of these motor signs appear. Many patients, looking back, recall a constellation of seemingly unrelated complaints that preceded the tremor by years. A loss of the sense of smell, called hyposmia, is common. So is a sleep disturbance in which the body acts out dreams instead of lying still, known as REM sleep behavior disorder. Chronic constipation and depression also feature in this prodromal period. These non-motor symptoms are not incidental, and as we will see, they may be the earliest visible traces of where the disease actually begins.

The Small Nucleus That Disappears

The center of the whole story is a structure in the midbrain called the substantia nigra pars compacta, named for its dark appearance, since its neurons are pigmented. This nucleus is small, but its neurons are special in two respects. They manufacture the neurotransmitter dopamine, and they send their long fibers up into a forebrain region called the dorsal striatum, forming a circuit known as the nigrostriatal pathway. Through this pathway the substantia nigra biases the basal ganglia, the brain's action-selection machinery, toward initiating and sustaining movement, and removing it leaves the machinery of voluntary action without its accelerator.

In Parkinson's disease these dopaminergic neurons die, slowly and progressively. One of the most consequential facts about the disorder comes from a meticulous quantitative autopsy study by Bernheimer and Hornykiewicz published in 1973. They found that the motor symptoms emerge only after roughly sixty percent of these neurons have already been lost, and the dopamine content of the striatum has fallen even further. The surviving cells compensate for a long time, working harder to cover the deficit, and by the time the tremor and slowness become obvious, the disease has been quietly advancing for years. The clinical onset is not the beginning of the illness, only the moment the brain's reserve finally runs out.

Lewy Bodies and the Protein That Misfolds

If you examine the surviving neurons of a Parkinson's brain under the microscope, you find a telltale abnormality inside them. In 1912, working in Alois Alzheimer's laboratory in Munich, a neuropathologist named Friedrich Lewy described round, dense, eosinophilic inclusion bodies sitting in the cytoplasm of affected neurons. These came to be called Lewy bodies, and they remain the histopathological signature of the disease, the feature a pathologist looks for to confirm the diagnosis after death.

For most of the twentieth century, what these inclusions were made of stayed a mystery, and the answer arrived in a remarkable convergence in 1997. Polymeropoulos and colleagues, reporting in Science, linked mutations in a gene called SNCA, which encodes a protein called alpha-synuclein, to rare inherited forms of Parkinson's. In the same year, Spillantini, Goedert, and their collaborators, writing in Nature, showed that alpha-synuclein was in fact the principal protein clumped inside Lewy bodies. The genetics and the pathology pointed at the same molecule. Alpha-synuclein is normally a soluble protein found at the tips of neurons, where it is thought to help regulate the release of neurotransmitter. In Parkinson's disease it misfolds, loses its normal shape, and aggregates into the insoluble tangles that define the disease.

From a Misfolded Protein to a Trembling Hand

These threads assemble into a cascade, a working sequence that links the molecular fault to the visible symptom. It begins with alpha-synuclein misfolding. The misfolded protein aggregates and accumulates into Lewy bodies. The neurons of the substantia nigra pars compacta sicken and die. As they die, the supply of dopamine to the dorsal striatum collapses. And once roughly sixty percent of those neurons are gone, the striatal dopamine deficit crosses the threshold at which the basal ganglia can no longer be biased toward action, and the motor symptoms appear. Each step rests on named, published evidence, and the cascade is precisely what the disease-modifying therapies now in development aim to interrupt, ideally near the top, before the neurons are lost.

It is worth being honest that the cascade is a working picture rather than a settled certainty. Exactly how misfolded alpha-synuclein kills neurons, and whether the visible Lewy bodies are the agents of damage or merely a burial site for something more toxic, remains genuinely debated. What is not in doubt is the endpoint, the loss of nigrostriatal dopamine, and that endpoint is what every effective treatment has so far targeted.

L-DOPA, the Drug That Changed Everything

For a long time there was nothing to offer beyond comfort, and then, across a single decade, three laboratories turned Parkinson's from an untreatable disease into a manageable one. In 1957, Arvid Carlsson in Lund showed that a molecule called L-DOPA, the natural precursor from which the body builds dopamine, could reverse the immobility he had induced in rabbits with the drug reserpine, work that contributed to his Nobel Prize in 2000. The crucial property of L-DOPA is that, unlike dopamine itself, it crosses the blood-brain barrier, so it can be given as a pill and then converted into dopamine inside the brain. In 1960, Oleh Hornykiewicz in Vienna examined the brains of people who had died with Parkinson's disease and found their striatal dopamine strikingly depleted, connecting the animal pharmacology to the human disorder. Then in 1967, George Cotzias at Brookhaven published a practical regimen of high-dose oral L-DOPA that actually worked in patients, the paper that turned a laboratory insight into a clinical revolution. More than half a century later, L-DOPA remains the single most effective treatment for the motor symptoms of the disease.

Electrodes in the Subthalamic Nucleus

L-DOPA was not the end of the story, because the brain can also be addressed directly. In 1987, a neurosurgeon in Grenoble named Alim-Louis Benabid noticed during stereotactic surgery that high-frequency electrical stimulation of the thalamus stopped the patient's tremor, and it stopped without his having to destroy any tissue, which had been the older and cruder approach. With his colleague Pierre Pollak, Benabid developed this observation into a chronic therapy in which thin electrodes are permanently implanted and connected to a pacemaker-like device, a technique now called deep brain stimulation. Through the 1990s the subthalamic nucleus, a small structure deep in the basal ganglia, became the standard target, particularly for patients with advanced disease whose response to L-DOPA had begun to fluctuate. Benabid received the Lasker-DeBakey Clinical Medical Research Award in 2014 for the work.

The Misconception That Matters Most

Here lies the point most often misunderstood. L-DOPA does not stop the disease. It is a transmitter-replacement therapy, refilling the dopamine that the dying neurons can no longer supply, and it does nothing to halt or slow the underlying loss of substantia nigra cells. The neurodegeneration grinds on beneath the treatment. Over a decade or so, as the remaining nerve terminals lose their capacity to buffer and store the drug, patients develop motor fluctuations, periods when the medication wears off before the next dose, and dyskinesias, involuntary writhing movements caused by the swings in dopamine. As of 2026, no approved therapy of any kind has been shown to slow the neurodegeneration itself. Everything we have treats the symptoms, not the cause.

The wider context fills out the picture. Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's, affecting roughly ten million people worldwide, and for the great majority of cases the cause is simply unknown. A minority are inherited, involving mutations in genes including SNCA, LRRK2, PARK2 (parkin), PINK1, and DJ-1. Environmental exposures such as certain pesticides, notably rotenone and paraquat, and head trauma raise the risk, while smoking and caffeine are, paradoxically and for reasons still unclear, associated with lower risk. One influential idea, the Braak staging model proposed in 2003, suggests the disease may actually begin not in the brain at all but in the olfactory bulb and the gut, then ascend through the brainstem into the cortex over years, which would explain why a lost sense of smell and chronic constipation can precede a tremor by so long.

Key Takeaways

Parkinson's disease, first described by James Parkinson in his 1817 essay and named by Charcot in the 1870s, is a progressive neurodegenerative disorder caused by the death of dopamine-producing neurons in the substantia nigra pars compacta, whose nigrostriatal projection to the dorsal striatum normally enables fluent voluntary movement; its clinical tetrad is bradykinesia (the obligatory cardinal sign), resting tremor, rigidity, and postural instability, frequently preceded by years of non-motor warning signs such as hyposmia, REM sleep behavior disorder, constipation, and depression, with motor symptoms surfacing only once roughly sixty percent of nigral neurons are gone. The molecular hallmark is the misfolding and aggregation of alpha-synuclein into Lewy bodies, identified through the converging 1997 work of Polymeropoulos and of Spillantini and Goedert, and the cascade runs from that misfolded protein through neuron death and striatal dopamine collapse to the trembling hand. The transformative treatment is L-DOPA (Carlsson 1957, Hornykiewicz 1960, Cotzias 1967), complemented by deep brain stimulation of the subthalamic nucleus (Benabid from 1987), but the durable and essential caveat is that none of this slows the underlying degeneration: L-DOPA replaces a missing transmitter without touching the disease, which continues to advance and eventually brings motor fluctuations and dyskinesias, and as of 2026 no therapy has been proven to halt the neuronal loss at the heart of the illness.